<DOC>
	<DOCNO>NCT00374686</DOCNO>
	<brief_summary>This study prophylactic Vs preemptive oral valganciclovir management cytomegalovirus infection adult renal transplant recipient look clinical pharmacoeconomic outcome</brief_summary>
	<brief_title>Study Prophylactic Vs Preemptive Valganciclovir</brief_title>
	<detailed_description>This study prophylactic Vs preemptive oral valganciclovir management cytomegalovirus infection adult renal transplant recipient look clinical pharmacoeconomic outcome . Patients risk CMV ( D+/R- , D+/R+ , D-/R+ ) randomize prophylaxis ( valganciclovir 900 mg qd 100 day , n=49 ) preemptive therapy ( 900 mg bid 21 day , n=49 ) CMV DNAemia ( CMV DNA level &gt; 2000 copies/ml â‰¥ 1 whole blood specimen quantitative PCR do weekly 16 week month 5 , 6 , 9 , 12 . Clinical virologic outcome measure pharmacoeconomic outcome analyze</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>All patient receive kidney transplant Washington University Medical Center March 2003 June 2004 . Age young 18 Refusal consent study Allergy ganciclovir severe illness serious justify randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>cytomegalovirus</keyword>
	<keyword>kidney</keyword>
	<keyword>transplantation</keyword>
	<keyword>valganciclovir</keyword>
	<keyword>preemptive</keyword>
</DOC>